FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pressure BioSciences’ PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and for Potential Clinical Diagnostics.”
Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers. The Chinese team from Westlake University (Hangzhou, China) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems. The Australian Proteome of Human Cancer (“ProCan”) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.
The biotechnology market is currently one of the largest industries in the world. Biotechnology is defined as technology that is used to modify or upgrade the biological system, in order to improve human welfare. However, despite being the largest sector globally, there are still various segments that haven’t been fully tapped into, presenting opportunities for a plethora of companies. In more technologically advanced nations, researchers have developed techniques and procedures that can completely cure or slow down the spread of specific ailments such as cancer or HIV. Notably, processes within the industry include microbiology, genetic engineering, biochemistry, among many others. And while there are many various types of medical conditions, the market is seeing a large spur of demand for therapeutic and diagnostic solutions such as red biotechnology, recombinant technology, and DNA sequencing. Overall, the presence of a multitude of companies focusing on regenerative therapies is expected to drive the biotechnology industry further forward. Moreover, some companies are also integrating advanced tech such as artificial intelligence and machine learning to more effectively combat individual medical cases. Furthermore, medical institutions are continually releasing new data to help improve the efficiency of medical technology. According to data compiled by Grand View Research, the global biotechnology market is expected to reach USD 727.1 Billion by 2025 while exhibiting a CAGR of 7.4%.
The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, it was estimated that 1.73 million in the U.S. were affected by cancer in 2018. Additionally, the report also suggested that 609,640 people passed away due to cancer. Overall, cancer research has accelerated over the past several decades. And typically, most cancer patients undergo various types of therapies such as chemotherapy or radiotherapy. Generally, these therapies use stimulants such as anti-cancer drugs or radiation to eradicate cancerous cells. However, the acceleration of the cancer technology market has introduced new procedures such as personalized treatments. Notably, formalin-fixed paraffin-embedded (FFPE) has become a crucial part of cancer research in labs nowadays. FFPE is a form of preservation and preparation for biopsy specimens that aid in the examination, experimental research, and diagnostic/drug development, according to Biochain. A tissue sample is first preserved by fixing it in formaldehyde to preserve the proteins and vital structures within the tissue. The tissues are frequently used in immunohistochemistry (IHC). The information provided from IHC can aid doctors in looking for signs of diseases such as cancer or Alzheimer’s disease. As the cancer treatment industry continues to advance, medical researchers are continuing to develop treatments and therapies that will effectively eliminate or limit the condition in patients. And with the number of cases emerging around the world, the biotechnology market is primed to witnessed substantial growth. “I see major advances in saving lives from cancer in the next 10 years by eliminating cancer health disparities. By implementing our research findings and changing how we organize the care to patients, we can reduce and eliminate cancer health disparities,” according to Karen M. Freund, M.D., M.P.H., Tufts Medical. ” We have shown through research that providing additional support to vulnerable patients and to their physicians, to provide education, support, and address the unique barriers they face, we can provide all patients the best care and best hope for a cure.”
For more information, please visit: Pressure Biosciences, Inc.
For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.